Fingerprint
Dive into the research topics of 'Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors
Jaume Capdevila, Michel Ducreux, Rocio García Carbonero, Enrique Grande, Thorvardur Halfdanarson, Marianne Pavel, Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar
Research output: Contribution to journal › Article › peer-review